NovaBay Pharmaceuticals Inc
AMEX:SDEV
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
N
|
NovaBay Pharmaceuticals Inc
AMEX:SDEV
|
US |
|
C
|
Central Garden & Pet Co
F:GP7A
|
US |
|
R
|
RWE AG
PSE:RWE
|
DE |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
US |
|
RTL Group SA
F:RRTL
|
LU |
|
I
|
iQ International AG
XBER:IQL
|
CH |
|
K
|
KDDI Corp
DUS:DIP
|
JP |
|
P
|
Pfizer Inc
DUS:PFE
|
US |
NovaBay Pharmaceuticals Inc
NovaBay Pharmaceuticals is a healthcare company that develops and sells products for eye care and skin care, with a focus on antimicrobial and hygiene-based treatments. Its best-known products are sold through doctors, pharmacies, and other healthcare channels, and they are aimed at everyday problems such as eyelid cleaning, irritation, and wound or skin hygiene. The company makes money by selling these products to distributors, clinics, pharmacies, and consumers, depending on the product and channel. In simple terms, it sits between drug development and consumer healthcare: it creates branded medical products, then earns revenue when those products are bought and used in the market. What makes NovaBay different is that it is not a broad drugmaker with a large pipeline of prescription medicines. Instead, it focuses on a narrower set of specialty products that are easier to understand and often used as part of routine care. That gives it a business tied to recurring everyday healthcare needs rather than one-time treatments.
NovaBay Pharmaceuticals is a healthcare company that develops and sells products for eye care and skin care, with a focus on antimicrobial and hygiene-based treatments. Its best-known products are sold through doctors, pharmacies, and other healthcare channels, and they are aimed at everyday problems such as eyelid cleaning, irritation, and wound or skin hygiene.
The company makes money by selling these products to distributors, clinics, pharmacies, and consumers, depending on the product and channel. In simple terms, it sits between drug development and consumer healthcare: it creates branded medical products, then earns revenue when those products are bought and used in the market.
What makes NovaBay different is that it is not a broad drugmaker with a large pipeline of prescription medicines. Instead, it focuses on a narrower set of specialty products that are easier to understand and often used as part of routine care. That gives it a business tied to recurring everyday healthcare needs rather than one-time treatments.
Record sales: NovaBay said Avenova ordered sales hit all-time highs on Amazon in March and April, with April sales more than 20% higher than a year ago.
Q1 growth: First-quarter total sales rose 12% to $2.6 million, driven mainly by stronger online Avenova sales.
Efficiency gains: Sales and marketing expense fell 50% to $1.1 million even as online sales improved, reflecting more efficient digital advertising.
Strategic shift: Management emphasized the company’s move to focus on eyecare and the dry eye market, which it described as large and growing.
New partnership: NovaBay completed training with Eyenovia and expects the co-marketing launch of clobetasol in the third quarter.
Profit impact: Net loss widened to $3.6 million, largely reflecting a noncash divestiture loss and other financing-related items.
